| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticarcinogenic Agents | 20 | 2013 | 362 | 3.240 |
Why?
|
| Mammary Neoplasms, Experimental | 17 | 2011 | 494 | 2.540 |
Why?
|
| Transcription Factor AP-1 | 21 | 2008 | 246 | 2.310 |
Why?
|
| Tetrahydronaphthalenes | 10 | 2011 | 116 | 2.100 |
Why?
|
| Breast Neoplasms | 59 | 2015 | 15694 | 1.850 |
Why?
|
| Receptors, Estrogen | 21 | 2015 | 2086 | 1.740 |
Why?
|
| Aromatase Inhibitors | 8 | 2014 | 305 | 1.360 |
Why?
|
| Selective Estrogen Receptor Modulators | 9 | 2011 | 145 | 1.310 |
Why?
|
| Tamoxifen | 15 | 2014 | 876 | 1.230 |
Why?
|
| Proto-Oncogene Proteins c-jun | 22 | 2008 | 166 | 1.180 |
Why?
|
| Receptors, Retinoic Acid | 8 | 2005 | 365 | 1.100 |
Why?
|
| Retinoids | 12 | 2011 | 164 | 1.090 |
Why?
|
| Estrogen Receptor Modulators | 7 | 2011 | 112 | 1.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 10 | 2014 | 840 | 1.070 |
Why?
|
| Chemoprevention | 8 | 2012 | 241 | 1.030 |
Why?
|
| Raloxifene Hydrochloride | 6 | 2011 | 47 | 0.800 |
Why?
|
| Genes, erbB-2 | 5 | 2008 | 229 | 0.780 |
Why?
|
| Breast | 7 | 2007 | 1344 | 0.770 |
Why?
|
| Quinazolines | 4 | 2009 | 923 | 0.720 |
Why?
|
| Cell Division | 9 | 2015 | 2489 | 0.670 |
Why?
|
| ErbB Receptors | 5 | 2011 | 2295 | 0.640 |
Why?
|
| Mice, Transgenic | 18 | 2011 | 4143 | 0.630 |
Why?
|
| Estrogens | 7 | 2007 | 751 | 0.610 |
Why?
|
| Mammary Tumor Virus, Mouse | 5 | 2008 | 122 | 0.600 |
Why?
|
| Estrogen Receptor alpha | 6 | 2014 | 701 | 0.600 |
Why?
|
| Mammary Glands, Animal | 5 | 2011 | 533 | 0.590 |
Why?
|
| Drug Delivery Systems | 3 | 2010 | 669 | 0.570 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2015 | 22 | 0.540 |
Why?
|
| Precancerous Conditions | 6 | 2009 | 1058 | 0.520 |
Why?
|
| Triazoles | 5 | 2014 | 617 | 0.480 |
Why?
|
| Cell Proliferation | 10 | 2015 | 7226 | 0.470 |
Why?
|
| Nitriles | 5 | 2014 | 906 | 0.470 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 203 | 0.470 |
Why?
|
| Receptor, ErbB-2 | 4 | 2011 | 2518 | 0.460 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2015 | 3552 | 0.450 |
Why?
|
| Genes, p53 | 2 | 2015 | 1090 | 0.430 |
Why?
|
| Growth Inhibitors | 3 | 2002 | 149 | 0.420 |
Why?
|
| Pyrazoles | 3 | 2013 | 1471 | 0.420 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2009 | 342 | 0.420 |
Why?
|
| Cyclins | 5 | 2008 | 456 | 0.420 |
Why?
|
| Sulfonamides | 3 | 2013 | 1823 | 0.410 |
Why?
|
| Cyclin D1 | 4 | 2009 | 576 | 0.400 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2011 | 2508 | 0.400 |
Why?
|
| Signal Transduction | 16 | 2015 | 11965 | 0.390 |
Why?
|
| Nicotinic Acids | 2 | 2007 | 33 | 0.380 |
Why?
|
| Female | 66 | 2015 | 141928 | 0.380 |
Why?
|
| Clinical Trials as Topic | 9 | 2011 | 3719 | 0.380 |
Why?
|
| Mice | 35 | 2015 | 34495 | 0.380 |
Why?
|
| Neoplasms | 11 | 2015 | 15193 | 0.380 |
Why?
|
| Drug Design | 2 | 2010 | 375 | 0.380 |
Why?
|
| E2F Transcription Factors | 2 | 2007 | 132 | 0.370 |
Why?
|
| Rotenone | 1 | 2009 | 35 | 0.360 |
Why?
|
| Doxycycline | 2 | 2008 | 178 | 0.350 |
Why?
|
| Disease Models, Animal | 8 | 2012 | 7222 | 0.350 |
Why?
|
| Tretinoin | 4 | 2000 | 623 | 0.340 |
Why?
|
| Calcium Compounds | 1 | 2008 | 9 | 0.340 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 5 | 2013 | 200 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2013 | 2594 | 0.340 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2011 | 2359 | 0.330 |
Why?
|
| Stem Cells | 1 | 2015 | 1213 | 0.330 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2003 | 639 | 0.320 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 334 | 0.320 |
Why?
|
| Animals | 40 | 2015 | 59536 | 0.320 |
Why?
|
| Antineoplastic Agents | 11 | 2012 | 14289 | 0.310 |
Why?
|
| Humans | 85 | 2015 | 261506 | 0.310 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 5539 | 0.300 |
Why?
|
| Cell Line, Tumor | 15 | 2015 | 14551 | 0.300 |
Why?
|
| G1 Phase | 3 | 2005 | 285 | 0.300 |
Why?
|
| Oncogenes | 3 | 2005 | 673 | 0.300 |
Why?
|
| Vitamin A | 1 | 2007 | 94 | 0.290 |
Why?
|
| Cell Cycle | 5 | 2009 | 2084 | 0.290 |
Why?
|
| Vitamin D | 1 | 2008 | 261 | 0.280 |
Why?
|
| Retinoid X Receptors | 5 | 2008 | 85 | 0.270 |
Why?
|
| Mutation | 10 | 2015 | 15179 | 0.270 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2004 | 311 | 0.270 |
Why?
|
| Gene Expression Regulation | 8 | 2011 | 4053 | 0.270 |
Why?
|
| Transforming Growth Factor beta | 3 | 2012 | 1130 | 0.260 |
Why?
|
| Preventive Medicine | 1 | 2005 | 28 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2011 | 8873 | 0.260 |
Why?
|
| Drug Evaluation, Preclinical | 5 | 2008 | 503 | 0.260 |
Why?
|
| RNA, Messenger | 10 | 2015 | 6150 | 0.250 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 1215 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-fos | 9 | 2005 | 123 | 0.250 |
Why?
|
| Peptide Fragments | 6 | 2008 | 1271 | 0.250 |
Why?
|
| DNA, Neoplasm | 5 | 2007 | 1910 | 0.250 |
Why?
|
| Patient Care Management | 1 | 2005 | 94 | 0.240 |
Why?
|
| Transcription Factors | 7 | 2004 | 5270 | 0.240 |
Why?
|
| Biomedical Research | 3 | 2009 | 806 | 0.230 |
Why?
|
| Tetradecanoylphorbol Acetate | 6 | 2004 | 226 | 0.220 |
Why?
|
| Transcriptional Activation | 8 | 2001 | 1070 | 0.210 |
Why?
|
| Drugs, Investigational | 1 | 2003 | 135 | 0.210 |
Why?
|
| Genes, Dominant | 3 | 2004 | 331 | 0.200 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2011 | 630 | 0.190 |
Why?
|
| Estrogen Antagonists | 3 | 2000 | 184 | 0.190 |
Why?
|
| Carcinoma | 2 | 2012 | 2578 | 0.190 |
Why?
|
| Celecoxib | 3 | 2013 | 200 | 0.190 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 6 | 2006 | 301 | 0.190 |
Why?
|
| Blotting, Western | 7 | 2010 | 3536 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 15 | 2010 | 5395 | 0.180 |
Why?
|
| Postmenopause | 2 | 2014 | 378 | 0.180 |
Why?
|
| Muscle Proteins | 1 | 2003 | 549 | 0.180 |
Why?
|
| Models, Biological | 6 | 2011 | 3254 | 0.180 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 1879 | 0.170 |
Why?
|
| Epidermal Growth Factor | 3 | 2009 | 423 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2009 | 4757 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2012 | 521 | 0.170 |
Why?
|
| Risk Assessment | 8 | 2013 | 6869 | 0.160 |
Why?
|
| Cell Growth Processes | 3 | 2009 | 342 | 0.160 |
Why?
|
| Tocopherols | 4 | 2014 | 19 | 0.160 |
Why?
|
| Gene Expression | 5 | 2015 | 3570 | 0.150 |
Why?
|
| Genes, jun | 5 | 2002 | 41 | 0.150 |
Why?
|
| Incidence | 4 | 2009 | 5673 | 0.150 |
Why?
|
| Biomarkers, Tumor | 8 | 2011 | 10331 | 0.150 |
Why?
|
| Transfection | 7 | 2009 | 2944 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2015 | 3821 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 2216 | 0.140 |
Why?
|
| Gene Expression Profiling | 6 | 2011 | 5159 | 0.140 |
Why?
|
| Transgenes | 3 | 2011 | 557 | 0.140 |
Why?
|
| Drug Administration Schedule | 3 | 2008 | 3472 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2008 | 15862 | 0.130 |
Why?
|
| Mice, Nude | 5 | 2015 | 4307 | 0.130 |
Why?
|
| Cell Line | 8 | 2003 | 5114 | 0.130 |
Why?
|
| Vitamin E | 3 | 2002 | 136 | 0.130 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2007 | 518 | 0.130 |
Why?
|
| Cell Differentiation | 8 | 2005 | 4078 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 4 | 2009 | 2314 | 0.120 |
Why?
|
| Selenium | 1 | 2014 | 47 | 0.120 |
Why?
|
| Epithelial Cells | 3 | 2011 | 1818 | 0.120 |
Why?
|
| Periodicals as Topic | 2 | 2008 | 338 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 2330 | 0.120 |
Why?
|
| Lymphocyte Activation | 5 | 1986 | 1688 | 0.120 |
Why?
|
| Smoking | 3 | 2013 | 2440 | 0.120 |
Why?
|
| Leukotriene E4 | 1 | 2013 | 2 | 0.120 |
Why?
|
| Cadherins | 2 | 2010 | 660 | 0.120 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2013 | 24 | 0.120 |
Why?
|
| Endoplasmic Reticulum | 1 | 2015 | 308 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 1823 | 0.120 |
Why?
|
| Phosphorylation | 7 | 2014 | 4804 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2014 | 5178 | 0.120 |
Why?
|
| Ki-67 Antigen | 2 | 2007 | 666 | 0.120 |
Why?
|
| Progesterone | 2 | 2007 | 513 | 0.110 |
Why?
|
| Prostaglandins | 1 | 2013 | 77 | 0.110 |
Why?
|
| Forecasting | 2 | 2006 | 694 | 0.110 |
Why?
|
| Genes, fos | 4 | 1999 | 53 | 0.110 |
Why?
|
| Transcription, Genetic | 7 | 2007 | 3154 | 0.110 |
Why?
|
| Estradiol | 3 | 2014 | 748 | 0.110 |
Why?
|
| Catechin | 1 | 2012 | 32 | 0.110 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 771 | 0.110 |
Why?
|
| Hydroxyurea | 1 | 2013 | 204 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 1077 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 2 | 2009 | 848 | 0.110 |
Why?
|
| Retinoblastoma Protein | 2 | 2004 | 335 | 0.100 |
Why?
|
| Cell Cycle Proteins | 3 | 2007 | 2045 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 4 | 2007 | 3101 | 0.100 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 161 | 0.100 |
Why?
|
| Interferon-gamma | 1 | 2015 | 1144 | 0.100 |
Why?
|
| Rats | 6 | 2006 | 6086 | 0.100 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2011 | 236 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 2 | 2013 | 483 | 0.100 |
Why?
|
| United States | 4 | 2014 | 15433 | 0.090 |
Why?
|
| Down-Regulation | 4 | 2011 | 2074 | 0.090 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1994 | 445 | 0.090 |
Why?
|
| PPAR gamma | 1 | 2011 | 229 | 0.090 |
Why?
|
| Placebos | 1 | 2011 | 437 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2008 | 1216 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 4938 | 0.090 |
Why?
|
| Response Elements | 2 | 2007 | 193 | 0.090 |
Why?
|
| Thiophenes | 2 | 2011 | 148 | 0.090 |
Why?
|
| Protein Phosphatase 2C | 1 | 2009 | 75 | 0.090 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 116 | 0.090 |
Why?
|
| Epiregulin | 1 | 2009 | 14 | 0.090 |
Why?
|
| T-Lymphocytes | 5 | 1986 | 3869 | 0.090 |
Why?
|
| Research Design | 2 | 2008 | 1544 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2014 | 2588 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 2 | 2009 | 1165 | 0.090 |
Why?
|
| Luciferases | 3 | 2006 | 445 | 0.080 |
Why?
|
| DNA-Binding Proteins | 6 | 2004 | 4821 | 0.080 |
Why?
|
| Growth Substances | 2 | 2002 | 300 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2006 | 3033 | 0.080 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 878 | 0.080 |
Why?
|
| Eicosanoids | 1 | 2008 | 31 | 0.080 |
Why?
|
| Cyclin D | 1 | 2008 | 37 | 0.080 |
Why?
|
| Apoptosis | 5 | 2006 | 7591 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1546 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1985 | 182 | 0.080 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2009 | 214 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2009 | 177 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 483 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 2 | 2012 | 1443 | 0.080 |
Why?
|
| Clone Cells | 3 | 2007 | 555 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2001 | 1555 | 0.080 |
Why?
|
| Transcription Factor DP1 | 1 | 2007 | 57 | 0.080 |
Why?
|
| Age Factors | 2 | 2008 | 5377 | 0.080 |
Why?
|
| E2F2 Transcription Factor | 1 | 2007 | 27 | 0.080 |
Why?
|
| E2F4 Transcription Factor | 1 | 2007 | 30 | 0.080 |
Why?
|
| beta Catenin | 2 | 2009 | 688 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 2054 | 0.080 |
Why?
|
| Internet | 1 | 2012 | 706 | 0.080 |
Why?
|
| Wnt Proteins | 1 | 2009 | 397 | 0.080 |
Why?
|
| Substrate Specificity | 1 | 2008 | 549 | 0.080 |
Why?
|
| Middle Aged | 11 | 2014 | 86204 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 1986 | 1664 | 0.070 |
Why?
|
| Drug Industry | 1 | 2007 | 88 | 0.070 |
Why?
|
| Adult | 11 | 2013 | 77950 | 0.070 |
Why?
|
| Protein Binding | 3 | 2007 | 3438 | 0.070 |
Why?
|
| Trans-Activators | 2 | 2004 | 1555 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1008 | 0.070 |
Why?
|
| Time Factors | 4 | 2007 | 12926 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2007 | 122 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2009 | 837 | 0.070 |
Why?
|
| Leuprolide | 1 | 2006 | 65 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2006 | 1082 | 0.070 |
Why?
|
| Zinc Fingers | 1 | 2007 | 205 | 0.070 |
Why?
|
| Receptors, Calcitriol | 1 | 2007 | 134 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2010 | 611 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 566 | 0.070 |
Why?
|
| Apigenin | 1 | 2006 | 12 | 0.070 |
Why?
|
| Radiation Chimera | 1 | 1986 | 30 | 0.070 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2006 | 16 | 0.070 |
Why?
|
| Proteome | 1 | 2010 | 561 | 0.070 |
Why?
|
| Risk Factors | 7 | 2014 | 17523 | 0.070 |
Why?
|
| E2F1 Transcription Factor | 1 | 2007 | 206 | 0.070 |
Why?
|
| Publishing | 1 | 2008 | 220 | 0.070 |
Why?
|
| Molecular Sequence Data | 6 | 2011 | 6089 | 0.070 |
Why?
|
| Drug Costs | 1 | 2007 | 144 | 0.070 |
Why?
|
| Genistein | 1 | 2006 | 73 | 0.070 |
Why?
|
| RNA | 2 | 2004 | 1013 | 0.070 |
Why?
|
| Vinblastine | 1 | 2006 | 453 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2007 | 447 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2007 | 1764 | 0.070 |
Why?
|
| Aspirin | 1 | 2009 | 455 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2006 | 330 | 0.070 |
Why?
|
| Piperidines | 2 | 2011 | 1035 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 2403 | 0.070 |
Why?
|
| Lung Neoplasms | 6 | 2009 | 11538 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 1046 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 460 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2007 | 1519 | 0.060 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2007 | 221 | 0.060 |
Why?
|
| Biomarkers | 5 | 2013 | 5047 | 0.060 |
Why?
|
| Patient Selection | 1 | 2012 | 2055 | 0.060 |
Why?
|
| Cellular Senescence | 1 | 2006 | 382 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2008 | 558 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 2315 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 622 | 0.060 |
Why?
|
| Mitosis | 1 | 2006 | 615 | 0.060 |
Why?
|
| Blood | 1 | 2004 | 156 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2007 | 3981 | 0.060 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2009 | 674 | 0.060 |
Why?
|
| Imidazoles | 1 | 2009 | 999 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 1 | 2004 | 188 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 542 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2004 | 1487 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2007 | 850 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 1678 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2002 | 528 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2011 | 849 | 0.060 |
Why?
|
| Multigene Family | 1 | 2004 | 425 | 0.060 |
Why?
|
| Genes, ras | 3 | 1996 | 667 | 0.060 |
Why?
|
| Genes, MHC Class II | 1 | 1983 | 67 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 543 | 0.060 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 74 | 0.060 |
Why?
|
| Mammography | 1 | 2009 | 1010 | 0.060 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 1665 | 0.060 |
Why?
|
| Genetic Counseling | 1 | 2005 | 380 | 0.050 |
Why?
|
| Pyridines | 1 | 2009 | 1244 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3639 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 1143 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2011 | 5637 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2001 | 72 | 0.050 |
Why?
|
| Protein Kinases | 2 | 1998 | 874 | 0.050 |
Why?
|
| DNA | 3 | 2001 | 2693 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2009 | 7548 | 0.050 |
Why?
|
| Benzamides | 1 | 2007 | 1832 | 0.050 |
Why?
|
| Dimerization | 2 | 2005 | 304 | 0.050 |
Why?
|
| Aged | 6 | 2014 | 70117 | 0.050 |
Why?
|
| Ovarian Neoplasms | 2 | 2015 | 4638 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 448 | 0.050 |
Why?
|
| Ligands | 4 | 2009 | 995 | 0.050 |
Why?
|
| Benzoates | 1 | 2002 | 136 | 0.050 |
Why?
|
| Base Sequence | 4 | 1996 | 4917 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2014 | 347 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2003 | 487 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 1986 | 1581 | 0.050 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2000 | 110 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2006 | 1152 | 0.050 |
Why?
|
| Cell Movement | 2 | 2006 | 2466 | 0.050 |
Why?
|
| Sequence Deletion | 2 | 1994 | 875 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2002 | 371 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2008 | 1423 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 492 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2012 | 2027 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2006 | 1498 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2001 | 476 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2013 | 1290 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2005 | 1026 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2009 | 5710 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 1756 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 1999 | 394 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 1547 | 0.040 |
Why?
|
| Lymph Nodes | 2 | 2006 | 2967 | 0.040 |
Why?
|
| Piperazines | 1 | 2007 | 2101 | 0.040 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 1997 | 95 | 0.040 |
Why?
|
| Europe | 1 | 1999 | 649 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2011 | 1064 | 0.040 |
Why?
|
| Survival Rate | 3 | 2006 | 12221 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 2001 | 341 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 5061 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2004 | 1549 | 0.040 |
Why?
|
| Software | 1 | 2004 | 1321 | 0.040 |
Why?
|
| Lymphoma | 1 | 1986 | 1467 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 5767 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2012 | 13658 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2005 | 32848 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 3890 | 0.040 |
Why?
|
| Rats, Inbred F344 | 2 | 1994 | 224 | 0.040 |
Why?
|
| Transformation, Genetic | 1 | 1996 | 57 | 0.040 |
Why?
|
| Algorithms | 1 | 2008 | 3890 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 97 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2010 | 2283 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2001 | 1620 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1997 | 798 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 4557 | 0.030 |
Why?
|
| Estrogen Receptor Antagonists | 1 | 2014 | 9 | 0.030 |
Why?
|
| Epithelium | 1 | 1997 | 720 | 0.030 |
Why?
|
| Androstenedione | 1 | 2014 | 18 | 0.030 |
Why?
|
| Diet | 1 | 2003 | 1440 | 0.030 |
Why?
|
| Histones | 1 | 2002 | 1466 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2007 | 3518 | 0.030 |
Why?
|
| Kinetics | 1 | 1997 | 2049 | 0.030 |
Why?
|
| Leucine Zippers | 1 | 1994 | 39 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1996 | 931 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2000 | 1129 | 0.030 |
Why?
|
| Carcinogens | 2 | 1993 | 384 | 0.030 |
Why?
|
| Teratocarcinoma | 1 | 1993 | 24 | 0.030 |
Why?
|
| Receptors, Progesterone | 2 | 2012 | 1392 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2013 | 17 | 0.030 |
Why?
|
| Mastectomy | 1 | 2000 | 1534 | 0.030 |
Why?
|
| Antigens, Surface | 2 | 1985 | 295 | 0.030 |
Why?
|
| Genes, Suppressor | 1 | 1993 | 25 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 4971 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 3343 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1993 | 300 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 1994 | 254 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 548 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 550 | 0.030 |
Why?
|
| Prognosis | 4 | 2013 | 21713 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 276 | 0.030 |
Why?
|
| Bone Demineralization, Pathologic | 1 | 2011 | 4 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 342 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 227 | 0.030 |
Why?
|
| Norpregnenes | 1 | 2011 | 5 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1991 | 138 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1993 | 396 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1992 | 202 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2011 | 163 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 3203 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2011 | 75 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2009 | 2450 | 0.020 |
Why?
|
| Obesity | 1 | 2004 | 2884 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2011 | 4233 | 0.020 |
Why?
|
| Adenocarcinoma | 2 | 2006 | 7789 | 0.020 |
Why?
|
| Fenretinide | 1 | 2011 | 96 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2011 | 803 | 0.020 |
Why?
|
| Premenopause | 1 | 2011 | 131 | 0.020 |
Why?
|
| Pyrrolidines | 1 | 2011 | 113 | 0.020 |
Why?
|
| Protein Stability | 1 | 2011 | 370 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 368 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2011 | 90 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 1618 | 0.020 |
Why?
|
| Androstadienes | 1 | 2011 | 165 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1993 | 408 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 14889 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 644 | 0.020 |
Why?
|
| Glutathione Transferase | 2 | 2001 | 359 | 0.020 |
Why?
|
| Genetic Markers | 1 | 1992 | 974 | 0.020 |
Why?
|
| Diphosphonates | 1 | 2011 | 262 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 476 | 0.020 |
Why?
|
| Digestive System Neoplasms | 1 | 2009 | 82 | 0.020 |
Why?
|
| Pyridones | 1 | 2011 | 348 | 0.020 |
Why?
|
| Authorship | 1 | 2008 | 53 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 827 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 2927 | 0.020 |
Why?
|
| Drug Synergism | 2 | 2006 | 1313 | 0.020 |
Why?
|
| Efficiency | 1 | 2008 | 99 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2011 | 428 | 0.020 |
Why?
|
| Lipids | 1 | 2011 | 644 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 1084 | 0.020 |
Why?
|
| Metformin | 1 | 2011 | 378 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 280 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2006 | 65 | 0.020 |
Why?
|
| Neoplasms, Ductal, Lobular, and Medullary | 1 | 2006 | 4 | 0.020 |
Why?
|
| Family | 1 | 2010 | 736 | 0.020 |
Why?
|
| Physician's Role | 1 | 2008 | 238 | 0.020 |
Why?
|
| G2 Phase | 1 | 2006 | 206 | 0.020 |
Why?
|
| Quality of Life | 1 | 2000 | 4532 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2006 | 132 | 0.020 |
Why?
|
| DNA, Antisense | 1 | 2005 | 42 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 1986 | 241 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 1985 | 56 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 703 | 0.020 |
Why?
|
| Neuraminidase | 1 | 1985 | 69 | 0.020 |
Why?
|
| Neuregulin-1 | 1 | 2005 | 83 | 0.020 |
Why?
|
| Species Specificity | 1 | 2007 | 777 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 1385 | 0.020 |
Why?
|
| Microcirculation | 1 | 2006 | 200 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2006 | 155 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1985 | 568 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2007 | 288 | 0.020 |
Why?
|
| Gamma Rays | 1 | 1986 | 242 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2006 | 886 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1985 | 521 | 0.020 |
Why?
|
| Integrins | 1 | 2006 | 262 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2009 | 677 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 1972 | 0.020 |
Why?
|
| Thymus Gland | 1 | 1986 | 294 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1985 | 585 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 1439 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1985 | 284 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6100 | 0.020 |
Why?
|
| Health Behavior | 1 | 2008 | 603 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 1053 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 2483 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1986 | 403 | 0.010 |
Why?
|
| Genetic Testing | 1 | 1992 | 1589 | 0.010 |
Why?
|
| Genetic Vectors | 2 | 2001 | 1694 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1985 | 558 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1983 | 88 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 750 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 1983 | 121 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 6942 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2008 | 787 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2002 | 43 | 0.010 |
Why?
|
| Liver | 1 | 2012 | 2961 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1983 | 139 | 0.010 |
Why?
|
| Antigens, Neoplasm | 2 | 1985 | 1506 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 852 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1985 | 747 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 3441 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1983 | 634 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2002 | 160 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 259 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6207 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2001 | 189 | 0.010 |
Why?
|
| Keratins | 1 | 2002 | 330 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2000 | 118 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2001 | 231 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 6682 | 0.010 |
Why?
|
| COS Cells | 1 | 2001 | 377 | 0.010 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2001 | 167 | 0.010 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2000 | 69 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 280 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1983 | 675 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1983 | 1213 | 0.010 |
Why?
|
| Gene Library | 1 | 2001 | 294 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 2000 | 157 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 1265 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2000 | 266 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 4549 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1985 | 1294 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 869 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 875 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 997 | 0.010 |
Why?
|
| Plasmids | 1 | 2001 | 837 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 10001 | 0.010 |
Why?
|
| Phenotype | 2 | 2000 | 6295 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1998 | 117 | 0.010 |
Why?
|
| Vimentin | 1 | 1999 | 253 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1998 | 164 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 1998 | 142 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1986 | 2358 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1998 | 248 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1997 | 682 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2001 | 778 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1996 | 355 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2002 | 1248 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1993 | 5319 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 3230 | 0.010 |
Why?
|
| Temperature | 1 | 1996 | 506 | 0.010 |
Why?
|
| Drug Therapy | 1 | 1995 | 205 | 0.010 |
Why?
|
| Male | 2 | 2014 | 123000 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 3578 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 21445 | 0.010 |
Why?
|
| Gastrin-Releasing Peptide | 1 | 1993 | 6 | 0.010 |
Why?
|
| Gastrins | 1 | 1993 | 55 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1991 | 329 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 31252 | 0.010 |
Why?
|
| Granulocytes | 1 | 1991 | 224 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1983 | 4367 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 29902 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2002 | 3341 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1996 | 1682 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1993 | 1681 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 1991 | 560 | 0.010 |
Why?
|
| Peptides | 1 | 1993 | 1479 | 0.000 |
Why?
|
| Adenoma | 1 | 1992 | 716 | 0.000 |
Why?
|
| Histocompatibility Antigens | 1 | 1985 | 74 | 0.000 |
Why?
|
| Macrophages | 1 | 1991 | 1304 | 0.000 |
Why?
|
| Cross Reactions | 1 | 1985 | 266 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2006 | 37905 | 0.000 |
Why?
|
| Epitopes | 1 | 1985 | 685 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1986 | 904 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1992 | 5437 | 0.000 |
Why?
|